Clinical trial
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or…
NCT00003056 · Baxalta now part of Shire, Industry · Terminated
Key facts
| NCT number | NCT00003056 |
|---|---|
| Title | Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation |
| Official title | Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) for GVHD Prophylaxis |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | cyclosporine, cyclosporine and methotrexate |
| Enrollment | 105 |
| Start date | Apr 1, 1997 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | May 24, 2004 |
| Last update posted | May 6, 2021 |
| Countries | Australia, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: